← Scroll for more →
ProPhase Labs, Inc. (PRPH)
Pharmaceutical Preparations
Latest Price
$0.36
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
--
P/B Ratio
--
Valuation metrics
adjust assumptions →Base FCF: $25M (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$46.17
+12634% upside
Institutional Ownership
1.5% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Sykon Capital LLC | 64.5K | -- | 0.46% | -- | 2025-12-31 |
| Vanguard Group Inc | 53.2K | -- | 0.38% | -- | 2025-12-31 |
| Jane Street Group, LLC | 22.0K | -- | 0.16% | -- | 2025-12-31 |
| StoneX Group Inc. | 20.0K | -- | 0.14% | -- | 2025-12-31 |
| HighTower Advisors, LLC | 18.8K | -- | 0.13% | -- | 2025-12-31 |
| Geode Capital Management, LLC | 16.3K | -- | 0.12% | -- | 2025-12-31 |
| Simplex Trading, LLC | 7.4K | -- | 0.05% | -- | 2025-12-31 |
| UBS Group AG | 3.1K | -- | 0.02% | -- | 2025-12-31 |